Trevor will take up this position on 1 December, coming from the Institut Laue-Langevin (ILL) in Grenoble, France, where he is Head of the Life Sciences Group and a Senior Fellow in Biology. He is also a Professor of Biophysics at Keele University in the UK.
As director of LINXS, he will lead the institute's work to maximise the exploitation of MAX IV, ESS and other large research facilities worldwide, and work to develop and strengthen national and international research that can benefit from using neutron and synchrotron light techniques. The overall goal is to establish a strong research and collaboration environment linked to MAX IV and ESS in order to capitalise on the potential for research to respond to global challenges, and to develop collaborations with universities – both nationally and internationally. As part of this, LINXS, will have a major mission to help motivate and push forward scientific, industrial and regional developments around Science Village Scandinavia (SVS).
In parallel, he will continue his multidisciplinary research in structural biology and in the field of life sciences - an area that includes diverse interests but with a particular focus on the molecular aspects of amyloid formation and the relationship to clinical manifestation in different types of amyloidosis such as transthyretin cardiomyopathy and polyneuropathy.
- I am incredibly happy that we have managed to recruit a researcher of Trevor Forsyth's caliber as director of LINXS; it shows what an attractive research environment Lund is. We are convinced that he, with his unique focus, large networks, and solid experience from other research facilities, will be a strong force to link the research at the facilities in Lund with other universities in Sweden and the world, says Professor Martin L. Olsson, deputy dean at the Faculty of Medicine.
- For the Faculty of Medicine, the appointment is also a strategic investment to link medical research in life sciences closer to MAX IV, and in the long term ESS. Recruitments like this can help us develop future treatments for the major public diseases, he concludes.